Multimodality Therapy for N2 Non-Small Cell Lung Cancer: An Evolving Paradigm.

ABSTRACT:

Background

Induction chemoradiation for resectable N2 non-small cell lung cancer (NSCLC) is used with the intent to optimize locoregional control, whereas induction chemotherapy given in systemic doses is meant to optimally target potential distant disease. However, the optimal preoperative treatment regimen is still unknown and practice patterns continue to vary widely. We compared multiinstitutional oncologic outcomes for N2 NSCLC from 4 experienced lung cancer treatment centers.

Methods

This collaborative retrospective study unites 4 major thoracic oncology centers. Patients with N2 NSCLC undergoing surgical resection after induction chemotherapy (CxT) or concurrent chemoradiation (CxRT) were included. Primary outcomes were overall and disease-free survival (OS and DFS).<

SUBMITTER: Spicer JD 

PROVIDER: S-EPMC6993842 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature